hero image

Biogen To Host Investor Webcast On Its Multiple Sclerosis Portfolio On December 12, 2018

November 19, 2018 News Release

Cambridge, Mass. – November 19, 2018 – Biogen (Nasdaq: BIIB) today announced it will host a live webcast and Q&A session to review its portfolio of commercial therapies and investigational new compounds for the treatment of multiple sclerosis.  The live webcast will begin at 8:00 a.m. ET with Tracey Dawson, vice president, Product Development and Commercialization Lead for Multiple Sclerosis, Aaron Deykin, M.D., vice president, head of Multiple Sclerosis and Acute Neurology Late Stage Clinical Development Unit, and Nathalie Franchimont, M.D., Ph.D., vice president and head of the Multiple Sclerosis Research and Early Development Unit. To access the live webcast, please go to the investors section of Biogen’s website at www.biogen.com/investors.  Following the live webcast, an archived version of the call will be available on the website.


About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. One of the world’s first global biotechnology companies, Biogen was founded in 1978 by Charles Weissmann, Heinz Schaller, Kenneth Murray and Nobel Prize winners Walter Gilbert and Phillip Sharp, and today has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics.


We routinely post information that may be important to investors on our website at www.biogen.com. To learn more, please visit www.biogen.com and follow us on social media – Twitter, LinkedIn, Facebook, YouTube.







David Caouette       

+1 617 679 4945




Matt Calistri

+1 781 464 2442



February 6, 2023
Biogen and Sage Therapeutics Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression

Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to treat major depressive disorder (MDD) and postpartum depression (PPD) Depression is a public health issue with significant unmet medical need CAMBRIDGE, Mass., Feb.

January 29, 2023
Lecanemab Receives Priority Review Status in Japan

TOKYO and CAMBRIDGE, Mass., Jan. 29, 2023 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, "Biogen") announced today that an application for